JP7321709B2 - がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン - Google Patents

がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン Download PDF

Info

Publication number
JP7321709B2
JP7321709B2 JP2018563076A JP2018563076A JP7321709B2 JP 7321709 B2 JP7321709 B2 JP 7321709B2 JP 2018563076 A JP2018563076 A JP 2018563076A JP 2018563076 A JP2018563076 A JP 2018563076A JP 7321709 B2 JP7321709 B2 JP 7321709B2
Authority
JP
Japan
Prior art keywords
polypeptide
sequence
seq
amino acids
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018563076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517508A (ja
JP2019517508A5 (enExample
Inventor
ガウダーナック，グスタフ
トルネス，アウドゥン
Original Assignee
ウルティモバックス エーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウルティモバックス エーエス filed Critical ウルティモバックス エーエス
Publication of JP2019517508A publication Critical patent/JP2019517508A/ja
Publication of JP2019517508A5 publication Critical patent/JP2019517508A5/ja
Priority to JP2022132995A priority Critical patent/JP2022171684A/ja
Application granted granted Critical
Publication of JP7321709B2 publication Critical patent/JP7321709B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018563076A 2016-06-02 2017-06-02 がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン Active JP7321709B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022132995A JP2022171684A (ja) 2016-06-02 2022-08-24 がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16172760.7 2016-06-02
EP16172760 2016-06-02
PCT/EP2017/063589 WO2017207814A1 (en) 2016-06-02 2017-06-02 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022132995A Division JP2022171684A (ja) 2016-06-02 2022-08-24 がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン

Publications (3)

Publication Number Publication Date
JP2019517508A JP2019517508A (ja) 2019-06-24
JP2019517508A5 JP2019517508A5 (enExample) 2020-07-16
JP7321709B2 true JP7321709B2 (ja) 2023-08-07

Family

ID=56132759

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018563076A Active JP7321709B2 (ja) 2016-06-02 2017-06-02 がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン
JP2022132995A Pending JP2022171684A (ja) 2016-06-02 2022-08-24 がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022132995A Pending JP2022171684A (ja) 2016-06-02 2022-08-24 がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン

Country Status (16)

Country Link
US (2) US11419927B2 (enExample)
EP (2) EP3463436B1 (enExample)
JP (2) JP7321709B2 (enExample)
AU (1) AU2017275782B2 (enExample)
CA (1) CA3026172A1 (enExample)
DK (1) DK3463436T3 (enExample)
ES (1) ES2965957T3 (enExample)
FI (1) FI3463436T3 (enExample)
HR (1) HRP20231650T1 (enExample)
HU (1) HUE065176T2 (enExample)
LT (1) LT3463436T (enExample)
PL (1) PL3463436T3 (enExample)
PT (1) PT3463436T (enExample)
RS (1) RS65007B1 (enExample)
SI (1) SI3463436T1 (enExample)
WO (1) WO2017207814A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2536830T3 (pl) 2010-02-16 2020-02-28 Ultimovacs As Polipeptydy
US11419927B2 (en) 2016-06-02 2022-08-23 Ultimovacs As Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
CN112368016A (zh) * 2018-06-29 2021-02-12 大鹏药品工业株式会社 抗肿瘤剂及其评价方法
CA3222077A1 (en) 2021-06-09 2022-12-15 Dana Michel A conjugate
WO2024083867A1 (en) * 2022-10-17 2024-04-25 Ultimovacs Asa Biomarker
WO2024126737A1 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A core and a conjugate
WO2024126758A2 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A nucleic acid molecule and a chimeric polypeptide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529873A (ja) 2002-04-12 2005-10-06 メダレックス インコーポレイテッド Ｃｔｌａ−４抗体を使用した治療の方法
JP2007277242A (ja) 2006-04-05 2007-10-25 Pfizer Prod Inc Ｃｔｌａ４抗体併用療法
JP2013519385A (ja) 2010-02-16 2013-05-30 オスロ ユニバーシティ ホスピタル エイチエフ ポリペプチド
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383424C (en) 1999-08-23 2011-02-15 Gordon Freeman Novel b7-4 molecules and uses therefor
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
ES2616258T3 (es) 2010-03-15 2017-06-12 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna
WO2012037551A2 (en) 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine
HK1212237A1 (en) 2012-08-31 2016-06-10 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
GB201223386D0 (en) 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
CN105073135A (zh) 2013-02-22 2015-11-18 库瑞瓦格有限责任公司 疫苗接种和抑制pd-1途径的组合
MX369709B (es) 2013-03-15 2019-11-19 Univ Pennsylvania Vacunación mejorada contra tirosinasa.
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
WO2015089114A1 (en) 2013-12-09 2015-06-18 Bullet Biotechnology, Inc. Specific virus-like particle-cpg oligonucleotide vaccines and uses thereof
US9903102B2 (en) 2013-12-27 2018-02-27 Xiamen Solex High-Tech Industries Co., Ltd. Concealed embedded component for a waterway system
EA035259B1 (ru) 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
WO2015128313A1 (en) 2014-02-25 2015-09-03 Deutsches Krebsforschungszentrum Rna viruses for immunovirotherapy
EP3142690B1 (en) 2014-05-13 2022-02-23 Bavarian Nordic A/S Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
JP2017515841A (ja) 2014-05-13 2017-06-15 バヴァリアン・ノルディック・アクティーゼルスカブ 腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法
EP3164157A4 (en) 2014-07-01 2018-02-28 Vicus Therapeutics, LLC Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them
WO2016007504A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
WO2016007499A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
JP2017522322A (ja) 2014-07-18 2017-08-10 アドバクシス， インコーポレイテッド 抗腫瘍応答を引き出すためのリステリアベースの免疫原性組成物
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
CA2966132A1 (en) 2014-10-23 2016-04-28 Institut Gustave Roussy Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
JP7305300B2 (ja) 2014-11-05 2023-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 併用免疫療法
EP3733201A1 (en) 2016-01-19 2020-11-04 Pfizer Inc Cancer vaccines
US11419927B2 (en) 2016-06-02 2022-08-23 Ultimovacs As Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529873A (ja) 2002-04-12 2005-10-06 メダレックス インコーポレイテッド Ｃｔｌａ−４抗体を使用した治療の方法
JP2007277242A (ja) 2006-04-05 2007-10-25 Pfizer Prod Inc Ｃｔｌａ４抗体併用療法
JP2013519385A (ja) 2010-02-16 2013-05-30 オスロ ユニバーシティ ホスピタル エイチエフ ポリペプチド
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｃａｎｃｅｒ Ｉｍｍｕｎｏｌ．Ｉｍｍｕｎｏｔｈｅｒ． （２０１１）， ６０， ｐ．１１３７－１１４６
Ｃａｎｃｅｒ Ｉｍｍｕｎｏｌ．Ｉｍｍｕｎｏｔｈｅｒ． （２０１６）， ６５， ｐ．５３７－５４９
Ｎａｔ． Ｒｅｖ． Ｃｌｉｎ． Ｏｎｃｏｌ．（２０１７）， １４， ｐ．１１５－１２８ （Ｅｐｕｂ ２０１６ Ｊｕｎ １）

Also Published As

Publication number Publication date
PT3463436T (pt) 2023-12-28
DK3463436T3 (da) 2023-12-18
PL3463436T3 (pl) 2024-03-04
EP4253419A2 (en) 2023-10-04
SI3463436T1 (sl) 2024-02-29
US20230049012A1 (en) 2023-02-16
RS65007B1 (sr) 2024-01-31
ES2965957T3 (es) 2024-04-17
US20190247482A1 (en) 2019-08-15
EP4253419A3 (en) 2024-05-22
HUE065176T2 (hu) 2024-05-28
AU2017275782A1 (en) 2019-01-24
US12168045B2 (en) 2024-12-17
LT3463436T (lt) 2024-01-25
CA3026172A1 (en) 2017-12-07
JP2022171684A (ja) 2022-11-11
EP3463436B1 (en) 2023-09-20
EP3463436A1 (en) 2019-04-10
FI3463436T3 (fi) 2023-12-04
WO2017207814A1 (en) 2017-12-07
HRP20231650T1 (hr) 2024-05-10
JP2019517508A (ja) 2019-06-24
US11419927B2 (en) 2022-08-23
AU2017275782B2 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
JP7321709B2 (ja) がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン
US20230277641A1 (en) Telomerase polypeptide vaccine for treating cancer
CN111093691A (zh) 蛋白质抗原及其用途
CA2934073A1 (en) Combination therapy with neoantigen vaccine
Kaufman Vaccines for melanoma and renal cell carcinoma
JP6698541B2 (ja) 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬
JP2022553192A (ja) 癌ワクチン
WO2024083866A1 (en) Cancer treatment
Llopiz et al. Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L
Naz et al. Prophylactic vaccines for prevention of prostate cancer
Llopiz-Khatchikian et al. Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L
Tabi Cancer vaccines
Prieto et al. Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L
HK40029579A (en) Protein antigens and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220824

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220824

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220905

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221004

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221024

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221025

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221111

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221115

C305 Report on accelerated appeal examination

Free format text: JAPANESE INTERMEDIATE CODE: C305

Effective date: 20221118

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221110

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230302

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230525

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230726

R150 Certificate of patent or registration of utility model

Ref document number: 7321709

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150